BioVersys Extends its Series C Round to CHF 32.6M


BioVersys, a Basel, Switzerland-based privately held clinical stage, multi-asset pharmaceutical company, extended its Series C funding to CHF 32.6M.

The round was led by AMR Action Fund. Carly Levine, PhD, of the AMR Action Fund will join BioVersys’ board of directors.

Led by Dr. Marc Gitzinger, BioVersys is a clinical stage pharmaceutical company focusing on research and development of small molecules acting on novel bacterial targets with applications in antimicrobial resistance (AMR) and targeted microbiome modulation.

The company intends to use the funds for the clinical development of BV100, a potential hospital antibiotic targeting the most drug-resistant bacterial pathogen, Acinetobacter baumannii.